BD Biosciences Revenue Grows 10 Percent in Fiscal Q1 on Strong Reagent, Instrument Sales
Becton Dickinson this week said that fiscal first-quarter revenue for its Biosciences division grew more than 10 percent while overall receipts at the life sciences company increased 10 percent as well.
Total receipts for the Biosciences unit during the three months ended Dec. 31, 2005, increased to $199.5 million from $180.8 million year over year. Around $85 million of that was from sales in the United States, representing a 12.7-percent increase in sales to that country. The remainder, or approximately $114 million, was in international sales, which represented an 8.7-percent increase in sales.
BD attributed the growth to strong sales of reagents and research instruments, particularly research analyzers and sorters.
BD said company-wide fiscal first-quarter revenue increased 10 percent to $1.4 billion, though "unfavorable" foreign-currency translations cost the firm 1 percent in lost growth.
Spending on R&D increased 11.7 percent in the quarter, jumping to $69.3 million from $62 million year over year, BD said.
The company said profits increased almost 40 percent to $217.9 million, or $.88 per basic share, from $195.4 million, or $.78 per basic share, during the same period last year.
BD did not break out its balance sheet for the quarter.
PerkinElmer's LAS Business Posts 8-Percent Decline in Q4 Revenue
PerkinElmer's Life and Analytical Sciences business unit this week reported revenue of $286.5 million for the fourth quarter of 2005, down 8 percent from $311.9 million in the fourth quarter of 2004.
The company attributed the decline to the "longer fiscal period in 2004 versus this year."
PerkinElmer posted total fourth-quarter 2005 revenue of $387.7 million, a 6-percent decrease over $411.6 million in the fourth quarter of 2004.
The company reported net income of $187.8 million, or GAAP earnings per share of $1.45, versus $37.9 million, or $.29 per share in the fourth quarter of 2004. The company said fourth quarter earnings include net divestiture gains of $1.47 per share.
PerkinElmer finalized the divestiture of its aerospace, semiconductor, and fluid-testing businesses during the quarter.
PerkinElmer spent $21 million on R&D during the fourth quarter of 2005, down from $22.3 million in the comparable period of 2004.
As of Jan. 1, PerkinElmer had cash and cash equivalents of $502.3 million.
Caliper Signs Quality-Control Deal with Artel
Caliper Life Sciences and Artel have entered a technology partnership to "strengthen quality assurance for automated liquid delivery systems," Artel announced this week.
The collaboration involves using Artel's multichannel verification system to test Caliper's Sciclone and RapidPlate automated handlers.
The partnership "gives end-users the option to optimize liquid handling equipment using the same methodology as the equipment manufacturer ... allowing for immediate integration and quality assurance," said Artel.
Financial details of the alliance were not released.